<DOC>
	<DOCNO>NCT00765674</DOCNO>
	<brief_summary>This study evaluate efficacy ( blood pressure lower effect ) safety aliskiren/amlodipine/hydrochlorothiazide patient moderate severe hypertension .</brief_summary>
	<brief_title>Efficacy Safety Aliskiren/Amlodipine/Hydrochlorothiazide Patients With Moderate-severe Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Male female 18 year age old msDBP msSBP requirement : 3A : Diagnosis moderate severe hypertension ( msSBP ≥ 160 mmHg &lt; 200 mmHg , and/or msDBP ≥ 100 mmHg &lt; 120 mmHg ) Visits 4 , 5 6 ( Qualifying BP visit ) In addition , visit immediately prior qualify visit , patient also msSBP ≥ 145 mmHg &lt; 200 mmHg msDBP ≥ 95 mmHg &lt; 120 mmHg ) Visits 3 , 5 5 . Patients meet two set requirement subsequent adjacent visit , i.e . either Visits 3 4 , Visits 4 5 , Visits 5 6 . OR 3B : msSBP ≥ 180 mmHg &lt; 200 mmHg msDBP ≥ 95 mmHg &lt; 120 mmHg , msDBP ≥ 110 mmHg &lt; 120 mmHg msSBP ≥ 150 mmHg &lt; 200 mmHg least one week treatment placebo ( Visit 3 ) . Continued use antihypertensive medicine use 4 hypertensive medicine study start Patients msSBP ≥ 200 mmHg msDBP ≥ 120 mmHg time placebo runin period discontinue study . Extremely elevated ( define ) blood pressure point study Pregnant lactate woman Premenopausal woman take accepted form birth control History evidence secondary form hypertension History cardiovascular condition Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>aliskiren</keyword>
	<keyword>antihypertensive</keyword>
	<keyword>hypertension</keyword>
	<keyword>renin inhibitor</keyword>
	<keyword>moderate-severe hypertension</keyword>
</DOC>